The number of Multidrug-Resistant Tuberculosis (MDR-TB) cases started on treatment in Canada from 2023 to 2028 reveals a steady trajectory. The forecasted data from 2024 indicates a slight uptick in cases from 19 to 20 by 2025, with stability in the numbers continuing through to 2028. This reflects a year-on-year increase of 5.26% in 2025, followed by no variation percentage yearly up to 2028. The compound annual growth rate (CAGR) over these five years is minimal, signifying near-constant levels throughout the period.
Future trends to watch for include:
- Potential emergence of new treatment protocols that might affect the number of cases receiving treatment.
- Public health initiatives and funding levels which could impact case statistics.
- Global health developments influencing cross-border disease management efforts.
